Metabolic Burden Measured by 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Is a Prognostic Factor in Patients with Small Cell Lung Cancer

키워드

참고문헌 (22)

1. Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
2. Aisner J, "Extensive-disease small-cell lung cancer : the thrill of victory : the agony of defeat", J Clin Oncol, 14, pp.658~665 (1996)
3. Mountain CF, "Revisions in the international system for staging lung cancer", Chest, 111, pp.1710~1717 (1997)
4. Yip D, "Predictive and prognostic factors in small cell lung cancer : current status", Lung Cancer, 28, pp.173~185 (2000)
5. Albain KS, "Determinants of improved outcome in small-cell lung cancer : an analysis of the 2, 580-patient Southwest Oncology Group data base", J Clin Oncol, 8, pp.1563~1574 (1990)
6. Pillot G, "Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer : a review", J Thorac Oncol, 1, pp.152~159 (2006)
7. Berghmans T, "Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project", J Thorac Oncol, 3, pp.6~12 (2008)
8. Ikenaga N, "Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors", Am Surg, 73, pp.1151~1157 (2007)
9. fluoro-2-deoxy-D-glucose, "Int J Radiat Oncol Biol Phys", 2004, 1295~1300
10. Lee YJ, "High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer", Clin Cancer Res, 15, pp.2426~2432 (2009)
11. Zhu D, "Prognostic significance of metabolic parameters measured by(18)F-fluorodeoxyglucose positron emission tomography", computed tomography in patients with small cell lung cancer, 2011, pp.73, 332~337
12. Fletcher JW, "Recommendations on the use of 18F-FDG PET in oncology", J Nucl Med, 49, pp.480~508 (2008)
13. Um SW, "Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer", J Thorac Oncol, 4, pp.1331~1336 (2009)
14. Elias AD, "Small cell lung cancer: state-of-the-art therapy in 1996", Chest, 112(4 Suppl), pp.251S~258S (1997)
15. Park S, "The impact of baseline and interim PET", CT parameters on clinical outcome in patients with diffuse large B cell lymphoma, 2012, pp.87, 937~940
16. Kumar V, "Robbins and Cotran pathologic basis of disease" (2009), Elsevier Saunders
17. Bruzzi P, "Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients", J Clin Oncol, 23, pp.5117~5125 (2005)
18. Hotta K, "Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer : Okayama Lung Cancer Study Group experience", Ann Oncol, 16, pp.1817~1823 (2005)
19. Hotta K, "Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer", Ann Oncol, 20, pp.829~834 (2009)
20. Hotta K, "Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer", J Thorac Oncol, 4, pp.311~317 (2009)
21. Kubota K, "Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer : Japan Clinical Oncology Group 9903", Clin Cancer Res, 11, pp.5534~5538 (2005)
22. Simon GR, "American College of Chest Physicians. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)", Chest, 132(3 Suppl), pp.324S~339S (2007)

관련 논문AI추천